Payment overview · 2025
General Payments
$432.38
12 reported records · 3 companies
Healthcare provider profile · identity verified
Marcelino Cintron, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GURABO, PR · NPI 1366433609
Verified facts
What the public records show
CMS Open Payments records show Marcelino Cintron, M.D. received $432.38 in general payments during 2025 across 12 reported records.
AstraZeneca Pharmaceuticals LP accounted for 81.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $352.64 | 81.6% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.74 | 12.7% | 1 | 2025 |
| Eli Lilly Export S.A. Puerto Rico Branch | Unresolved — no canonical attribution shown | $25.00 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $432.38 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $288.99 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $54.74 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $50.00 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $25.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 697 | 144 |
| Famotidine | Famotidine | 603 | 156 |
| Atorvastatin Calcium | Atorvastatin Calcium | 531 | 190 |
| Amlodipine Besylate | Amlodipine Besylate | 446 | 155 |
| Lisinopril | Lisinopril | 392 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 339 | 98 |
| Omeprazole | Omeprazole | 302 | 85 |
| Synthroid | Levothyroxine Sodium | 301 | 75 |
| Metformin Hcl | Metformin Hcl | 297 | 100 |
| Losartan Potassium | Losartan Potassium | 266 | 99 |
| Tamsulosin Hcl | Tamsulosin Hcl | 249 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 229 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 226 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 207 | 47 |
| Baclofen | Baclofen | 188 | 63 |
| Diclofenac Sodium | Diclofenac Sodium | 176 | 51 |
| Clonazepam | Clonazepam | 175 | 50 |
| Temazepam | Temazepam | 175 | 35 |
| Diclofenac Potassium | Diclofenac Potassium | 173 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 61 |
| Simvastatin | Simvastatin | 168 | 55 |
| Montelukast Sodium | Montelukast Sodium | 159 | 57 |
| Nabumetone | Nabumetone | 131 | 49 |
| Sertraline Hcl | Sertraline Hcl | 119 | 27 |
| Meclizine Hcl | Meclizine Hcl | 115 | 39 |
| Irbesartan | Irbesartan | 114 | 41 |
| Meloxicam | Meloxicam | 114 | 52 |
| Azithromycin | Azithromycin | 108 | 87 |
| Donepezil Hcl | Donepezil Hcl | 107 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 106 | 33 |
| Trazodone Hcl | Trazodone Hcl | 101 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 100 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 32 |
| Finasteride | Finasteride | 93 | 26 |
| Tramadol Hcl | Tramadol Hcl | 91 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 21 |
| Buspirone Hcl | Buspirone Hcl | 76 | 22 |
| Eliquis | Apixaban | 73 | 18 |
| Metformin Hcl Er | Metformin Hcl | 71 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 58 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 20 |
| Alendronate Sodium | Alendronate Sodium | 68 | 22 |
| Glimepiride | Glimepiride | 66 | 21 |
| Jardiance | Empagliflozin | 65 | 19 |
| Farxiga | Dapagliflozin Propanediol | 64 | 19 |
| Pentoxifylline | Pentoxifylline | 63 | 14 |
| Latanoprost | Latanoprost | 61 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 61 | 25 |
| Atenolol | Atenolol | 60 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 22 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 59 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 15 |
| Azelastine Hcl | Azelastine Hcl | 57 | 35 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 57 | 20 |
| Sucralfate | Sucralfate | 56 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 55 | 16 |
| Enalapril Maleate | Enalapril Maleate | 54 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 54 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 53 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 24 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 52 | 14 |
| Ezetimibe | Ezetimibe | 51 | 18 |
| Glipizide | Glipizide | 50 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 11 |
| Dexamethasone | Dexamethasone | 46 | 36 |
| Furosemide | Furosemide | 46 | 19 |
| Lorazepam | Lorazepam | 45 | suppressed |
| Memantine Hcl | Memantine Hcl | 45 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | 13 |
| Candesartan Cilexetil | Candesartan Cilexetil | 38 | 11 |
| Glipizide Er | Glipizide | 38 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 38 | 13 |
| Fenofibrate | Fenofibrate | 37 | 14 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 37 | 24 |
| Rivastigmine | Rivastigmine | 37 | suppressed |
| Carvedilol | Carvedilol | 36 | 13 |
| Mometasone Furoate | Mometasone Furoate | 34 | 20 |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Ciclopirox | Ciclopirox | 30 | 11 |
| Ketoconazole | Ketoconazole | 30 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | 14 |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Ramipril | Ramipril | 28 | 11 |
| Synjardy | Empagliflozin/Metformin Hcl | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 17 |
| Humulin R | Insulin Regular, Human | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 26 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 22 |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | 12 |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 23 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 23 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | 11 |
| Celecoxib | Celecoxib | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Ibu | Ibuprofen | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Clotrimazole | Clotrimazole | 19 | 13 |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 18 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 18 | 12 |
| Albuterol Sulfate | Albuterol Sulfate | 17 | 15 |
| Cimetidine | Cimetidine | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 15 | suppressed |
| Benzonatate | Benzonatate | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 14 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Anastrozole | Anastrozole | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Folic Acid | Folic Acid | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 12 |
| Permethrin | Permethrin | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $432.38 · 12 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, JARDIANCE, MOUNJARO, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error